T1	PROC 47 105	Estudio en fase III, aleatorizado, doble ciego, controlado
T2	PROC 112 146	evaluar la eficacia y la seguridad
T3	PROC 153 170	terapia combinada
#1	AnnotatorNotes T3	C0009429; Combined Modality Therapy; Therapeutic or Preventive Procedure
T4	CHEM 175 181	VX-121
T5	LIVB 185 192	sujetos
#2	AnnotatorNotes T5	C0681850; Study Subject; Group
T6	DISO 197 214	fibrosis quística
#3	AnnotatorNotes T6	C0010674; Cystic Fibrosis; Disease or Syndrome
T7	DISO 229 246	Fibrosis quística
#4	AnnotatorNotes T7	C0010674; Cystic Fibrosis; Disease or Syndrome
T8	LIVB 279 285	sujeto
#5	AnnotatorNotes T8	C0681850; Study Subject; Group
T9	LIVB 292 305	representante
#6	AnnotatorNotes T9	C0600419; Patient Agent; Group | C1708966; Medical Equipment Company Technician or Representative; Professional or Occupational Group
T10	PROC 376 400	consentimiento informado
#7	AnnotatorNotes T10	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T11	PROC 402 405	ICF
T12	PROC 501 508	visitas
T13	PROC 533 544	tratamiento
#8	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	PROC 581 603	pruebas de laboratorio
#9	AnnotatorNotes T14	C0022885; Laboratory Procedures; Laboratory Procedure
T15	PROC 609 631	pautas anticonceptivas
T16	PROC 640 654	procedimientos
T17	Neg_cue 671 673	No
T18	PROC 684 698	consentimiento
T19	Negated 684 698	consentimiento
T20	PROC 776 787	Tratamiento
#10	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	CHEM 804 811	fármaco
#11	AnnotatorNotes T21	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T22	PROC 856 884	interrupción(es) del fármaco
T23	Neg_cue 927 929	no
T24	PROC 930 968	interrumpió permanentemente el fármaco
T26	PROC 996 1003	visitas
T27	PROC 1032 1038	visita
T28	PROC 1065 1076	tratamiento
#12	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	PROC 1134 1156	régimen de tratamiento
T30	DISO 1173 1175	FQ
#13	AnnotatorNotes T30	C0010674; Cystic Fibrosis; Disease or Syndrome
T31	DISO 1275 1287	comorbilidad
#14	AnnotatorNotes T31	C0206308; Dual diagnosis (psychiatry); Finding | C1275743; Co-morbid conditions; Finding
T32	LIVB 1306 1318	investigador
#15	AnnotatorNotes T32	C0035173; Research Personnel; Professional or Occupational Group
T36	PROC 1399 1425	administración del fármaco
T37	LIVB 1441 1447	sujeto
#16	AnnotatorNotes T37	C0681850; Study Subject; Group
T39	LIVB 1509 1516	mujeres
#17	AnnotatorNotes T39	C0043210; Woman; Population Group | C0242665; wife; Family Group
T40	PROC 1533 1551	prueba de embarazo
#18	AnnotatorNotes T40	C0032976; Pregnancy Tests; Diagnostic Procedure
T42	Neg_cue 1552 1560	negativa
T43	PROC 1567 1573	visita
T44	Date 1578 1583	día 1
T46	CHEM 1622 1629	fármaco
#19	AnnotatorNotes T46	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T47	DISO 1658 1683	intolerancia a las drogas
T50	LIVB 1750 1756	sujeto
#20	AnnotatorNotes T50	C0681850; Study Subject; Group
T51	LIVB 1772 1784	investigador
#21	AnnotatorNotes T51	C0035173; Research Personnel; Professional or Occupational Group
T52	LIVB 1795 1802	sujetos
#22	AnnotatorNotes T52	C0681850; Study Subject; Group
T53	DISO 1823 1830	alergia
#23	AnnotatorNotes T53	C0020517; Hypersensitivity; Pathologic Function
T54	DISO 1833 1850	hipersensibilidad
#24	AnnotatorNotes T54	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T55	CHEM 1854 1861	fármaco
#25	AnnotatorNotes T55	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T56	Date 1893 1899	actual
T58	Neg_cue 1949 1951	no
T61	PROC 2013 2040	estudio no intervencionista
T64	PROC 2056 2079	estudios de observación
#26	AnnotatorNotes T64	C1518527; Observational Study; Research Activity
T65	PROC 2085 2105	estudios de registro
T66	PROC 2135 2157	extracciones de sangre
#27	AnnotatorNotes T66	C0419338; Blood withdrawal NOS; Diagnostic Procedure
T67	Neg_cue 2158 2161	sin
T68	PROC 2165 2191	administración del fármaco
T71	PROC 433 459	formulario de asentimiento
T25	Negated 930 968	interrumpió permanentemente el fármaco
T35	Negated 1533 1551	prueba de embarazo
T38	LIVB 1452 1459;1477 1497	Mujeres período de lactancia
T76	LIVB 1452 1471	Mujeres embarazadas
T78	PROC 1906 1943	ensayo de un fármaco en investigación
T59	PROC 1959 1976	estudio principal
T60	Negated 1959 1976	estudio principal
T62	Negated 2165 2191	administración del fármaco
